These CMV-CD19-CAR-T cells are studied in CD19+ tumor bearing murine models, and have potential utility for B cell non-Hodgkin’s lymphoma treatment (101, 102). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.